The verdict
Our read at a glance.
Whether LL-37 and its engineered analogs deliver the antimicrobial, wound-healing, and immune benefits attributed to them in people, beyond the laboratory.
- The signal
- LL-37 has clear antimicrobial and immune-signaling activity in the laboratory, and small early human studies have tested the natural peptide for hard-to-heal leg ulcers and, by direct injection, for melanoma. Most engineered analogs remain preclinical. There is no large or confirmatory human trial establishing benefit, and LL-37 can also be pro-inflammatory in some settings.
- The unknown
- Whether any LL-37 analog can be given safely and usefully in people, given that the same peptide can either help or drive inflammation depending on context.
- Our read
- A real and active research field, not a finished product. LL-37 genuinely does interesting things in the lab and has had small early human tests, but engineered analogs are mostly preclinical and the peptides sold online have no human evidence.
The mechanism
How it works.
LL-37 is the active fragment released when the human cathelicidin precursor is cleaved, a short positively charged peptide that is drawn to the negatively charged surface of microbes and inserts into their membranes to break them apart. Beyond killing microbes directly, it binds receptors on immune cells, where it can either dampen or stoke inflammation depending on context, and it supports wound repair. Engineered analogs tweak the sequence to keep the antimicrobial action while resisting breakdown and lowering toxicity. Most analogs sit at the laboratory stage, with only small early human studies of the natural peptide, so a safe, effective human therapy is not established.
Safety & regulatory boundary
The consequential part.
No LL-37 analog is an approved medicine. The human evidence is limited to small early-phase studies of the natural peptide, not the products sold online. LL-37 marketed as a research-chemical peptide is unapproved, of uncertain identity and purity, and its pro-inflammatory potential and lack of dosing data make self-use risky. LL-37 has also been implicated in inflammatory skin disease, so more is not automatically better.
What's next
What we're watching.
Whether any engineered LL-37 analog reaches a controlled clinical trial with a real outcome, and how the natural peptide performs in larger wound or oncology studies.
Context
Why this is discussed.
LL-37 is a natural part of human immune defense that kills bacteria and supports healing, which makes it attractive for infections, wounds, and inflammation that standard treatments handle poorly.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · RECRUITING · 2022-01-01
ClinicalTrials.gov · PHASE2 · RECRUITING · 2024-01-01
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-04
ClinicalTrials.gov · COMPLETED · 2021-11-03
ClinicalTrials.gov · COMPLETED · 2024-07-01
ClinicalTrials.gov · NOT_YET_RECRUITING · 2025-12-30
ClinicalTrials.gov · NA · COMPLETED · 2025-03-01
ClinicalTrials.gov · NA · ACTIVE_NOT_RECRUITING · 2010-07
Indexed literature (PubMed)12
Verma SC et al. · J Clin Invest · 2024
Fabisiak A et al. · Pharmacol Rep · 2016
Miao S et al. · Pharmacol Res · 2024
Voronko OE et al. · Int J Mol Sci · 2025
Aloul KM et al. · Front Immunol · 2022
Golec M · Ann Agric Environ Med · 2007
Shih CC et al. · Biomed Pharmacother · 2023
Lee JY et al. · Diagn Microbiol Infect Dis · 2020
Xhindoli D et al. · Biochim Biophys Acta · 2016
Wang G et al. · Adv Exp Med Biol · 2019
Svensson D et al. · Inflamm Res · 2025
Tjabringa GS et al. · Pulm Pharmacol Ther · 2005
Keep reading